✦ LIBER ✦

Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study

✍ Scribed by G. Fénelon; S. Giménez-Roldán; J. L. Montastruc; F. Bermejo; F. Durif; I. Bourdeix; J.-J. Péré; L. Galiano; J. Schadrack; on behalf of the INT-02 Study Group

Publisher: Springer
Year: 2003
Tongue: English
Weight: 121 KB
Volume: 110
Category: Article
ISSN: 1435-1463
DOI: 10.1007/s00702-002-0799-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combining entacapone with levodopa/DDCI

Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson’s Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study

✍ M. Onofrj; A. Thomas; F. Vingerhoets; W. Martin; S. Giménez-Roldán; J.-P. Azulay 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 292 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre